Lipopolysaccharide (LPS) is a crucial component of gram-negative bacteria's cell walls, which is required for bacterial cell integrity, survival, and protection against environmental stress. LPS has the capacity to directly alter disease susceptibility as well as the immune system. LPS spreads into the extracellular environment, making it a crucial receptor for numerous bacteriophages. As a result, LPS and the phage life cycle are intimately linked, and phage predation puts bacteria under strong selection pressure to alter their LPS.
Fig.1 Key virulence factors important in the pathogenesis of P. aeruginosa infections. (Killough, et al., 2022)
LPS plays a pivotal role as a major virulence factor in P. aeruginosa, contributing to its pathogenicity. It is an essential and integral component of the typical cell envelope found in the majority of gram-negative bacteria (GNB).
Fig.2 Structure of LPS from P. aeruginosa. (Barkleit, et al., 2008)
LPS is an attractive antigen for vaccine development since it is required by practically all GNBs. Biosynthesis routes are appealing candidates for antibiotic development, particularly because these mechanisms frequently utilize substrates not found in humans. Due to the potential application of LPS, CD BioGlyco's custom LPS production service especially P. aeruginosa LPS production service is a nice choice to study the vaccine application of LPS for researchers.
In order to develop innovative antimicrobial solutions targeting P. aeruginosa and other gram-negative infections, it is crucial to gain comprehensive insights into the enzymes involved in LPS biosynthesis, understand the gene regulatory mechanisms and elucidate the structure of LPS. CD BioGlyco, a leading service provider, offers expertise in LPS-related research and development. The identification of therapeutics that can inhibit the lipid A modification pathways will play a pivotal role in overcoming CAMP resistance. Additionally, exploring the potential of "natural" antimicrobials such as phages and bacteriocins that utilize LPS as a receptor can provide targeted therapeutic options. Besides LPS, other P. aeruginosa polysaccharide antigens such as Alginate Polysaccharide, Pel Polysaccharide, and Psl Polysaccharide are also some attractive molecules in vaccine research and development.
Fig.3 Three typical structures of LPS. (CD BioGlyco)
Our vaccine development platform provides a wide range of high-quality, excellent, and suitable custom production services for our clients worldwide.
We provide custom purification services for our clients according to their needs to produce different molecular weight LPS.
Our service team is available to respond to inquiries from clients around the world promptly.
We employ outstanding lab operators to handle these production services.
CD BioGlyco is a company with extensive glycan chemistry research experience and aims to be clients' best glycan research cooperator. We have established a well-equipped platform for production and quality control. Please feel free to contact us for more detailed information and any questions.
References:
